^
    Back
    Association details:
    Biomarker:MPRIP-ROS1 fusion
    Cancer:Non Small Cell Lung Cancer
    Drug:Xalkori (crizotinib) (ALK inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C4 – Case Studies
    Source:
    Onco Targets Ther
    Title:

    Identification of a Novel MPRIP-ROS1 Fusion and Clinical Efficacy of Crizotinib in an Advanced Lung Adenocarcinoma Patient: A Case Report

    Published date:
    10/13/2020
    Excerpt:
    We reported a novel MPRIP-ROS1 fusion identified in this advanced lung adenocarcinoma case….the treatment has lasted 16 months, and the patient is still in follow-up showing sustained response to crizotinib.
    DOI:
    10.2147/OTT.S270961